Why this distinction is the whole ballgame for compounded GLP-1s
Compounded semaglutide and tirzepatide are made by pharmacies, not the brand manufacturers — and the quality controls behind them vary enormously depending on which kind of pharmacy is making them. That is the 503A-vs-503B line, and it is the single most useful thing to understand before buying.
A 503A pharmacy is the traditional model: it compounds a medication against a prescription written for you specifically. It is licensed by a state board of pharmacy, but it is not registered with the FDA and is not inspected against the drug-manufacturing quality standards (cGMP) that apply to actual manufacturers. Quality is real but depends on the individual pharmacy.
A 503B“outsourcing facility” is a step up in accountability: it voluntarily registers with the FDA, follows cGMP manufacturing standards, submits to FDA inspection, and can produce larger batches. For a mass-compounded drug like semaglutide, that inspection and batch-quality regime matters. It is the strongest compounding tier.
The caveat that must never get lost: neither is an FDA-approved finished drug.A 503B facility being well-regulated is not the same as the compounded product having gone through the FDA approval process that brand Wegovy, Ozempic, Mounjaro, and Zepbound did. A 503B is the best compounding option and far safer than an unregistered seller — but “503B” and “FDA-approved” are not the same words.